Clinical Efficacy and Bone Turnover Markers of Buzhong Yiqitang in Treatment of Senile Osteoporotic Vertebral Compression Fracture After Operation Based on ''Spleen Governing Muscle''
10.13422/j.cnki.syfjx.20221323
- VernacularTitle:基于“脾主肌肉”探讨补中益气汤对骨质疏松椎体压缩性骨折术后临床疗效及骨转换标志物的影响
- Author:
Yadong WU
1
;
Zhenguang GUO
1
;
Wenjie DENG
1
;
Xiaoyan QI
2
;
Jingwei XU
1
;
Yuzhou LU
1
;
Bocheng LIANG
3
Author Information
1. Rizhao Hospital of Traditional Chinese Medicine， Rizhao 276800， China
2. People's Hospital of Rizhao， Rizhao 276826， China
3. The Second Affiliated Hospital of Zhejiang Chinese Medical University， Hangzhou 310005， China
- Publication Type:Journal Article
- Keywords:
Buzhong Yiqitang;
senile osteoporotic vertebral compression fracture;
bone turnover markers;
quality of life
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2022;28(17):91-97
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo study the effect on quality of life and the bone turnover markers of Buzhong Yiqitang in the treatment of senile osteoporotic vertebral compression fracture （OVCF， syndrome of Qi deficiency in spleen and stomach） after operation based on ''spleen governing muscle''. MethodA total of 135 senile patients with OVCF treated by percutaneous kyphoplasty in Rizhao Hospital of Traditional Chinese Medicine from January 2020 to January 2021 were enrolled in this study. They were randomly assigned to two groups on the basis of block randomization at a ratio of 2∶1 （90 cases in the observation group and 45 cases in the control group）. Both groups were administrated with calcitriol capsules （0.5 μg·d-1） and caltrate D （1 200 mg·d-1） for basic treatment of osteoporosis. The observation group was additionally treated with Buzhong Yiqitang. Bone mineral density （BMD）， procollagen type Ⅰ N-terminal propeptide （PINP）， osteocalcin （OST）， β cross-linked C-telopeptide of type 1 collagen （β-CTx）， appendicular skeletal muscle mass index （ASMI）， and quadriceps muscle strength were compared between the two groups before and 6， 12 months after treatment. Additionally， traditional Chinese medicine （TCM） symptom score and visual analogue score （VAS） before and 3， 6 months after treatment， as well as quality of life questionnaire of the European Foundation for osteoporosis （QUALEFFO） score before and 3， 6， 12 months after treatment， were compared between the two groups. ResultA total of 85 patients in the observation group and 41 patients in the control group were followed up. The general curative effect of the observation group was better than that of the control group （χ2=10.503， P<0.05）. Specifically， the observation group had higher PINP， BMD， ASMI， and quadriceps muscle strength but lower β-CTx， TCM symptom score， VAS， and QUALEFFO score than the control group （P<0.05， P<0.01）. No adverse reactions related to Buzhong Yiqitang were observed. ConclusionBuzhong Yiqitang can regulate bone metabolism indexes， promote osteogenesis， increase bone density， enhance skeleton appendiculare and quadriceps muscle strength， relieve clinical symptoms， and improve quality of life in patients with senile OVCF （syndrome of Qi deficiency in spleen and stomach）， being worthy of promotion in clinical application.
